We demonstrate that SOX13 directly targets SCAF1 and suppresses ferroptosis possibly via inducing the production of NADPH, which is a potential therapeutic strategy to increase chemosensitivity for advanced GC patients. This evidence concerns the gene SOX13 and gastric cancer.